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Q Which treatments are safe  
and effective for chronic sinusitis?
 for adults with chronic rhino- 
 sinusitis (crs), intranasal ste-
roid (ins) therapy is more likely than 
placebo to improve symptoms (50% vs 
32%; strength of recommendation [SOR]: 
A, systematic reviews).  
Nasal saline irrigation (SI) alleviates 
symptoms better than no therapy (SOR: A, 
systematic reviews), but it’s probably not 
as effective as INS treatment (SOR: B, ran-
domized controlled trial [RCT] with wide 
confidence interval).   
Long-term (12 weeks) macrolide ther-
apy doesn’t alter patient-oriented qual-
ity-of-life measures (SOR: A, systematic 
reviews).
Endoscopic sinus surgery improves 
CRS symptoms—nasal obstruction, dis-
charge, and facial pain—over baseline 
(SOR: A, systematic reviews).  Surgery and 
medical therapy appear about equivalent 
in terms of symptom improvement and 
quality-of-life measures (SOR: B, system-
atic reviews of low-quality RCTs).
Evidence summary
The TABLE1-4 shows the major results of the 
meta-analyses for the various medical ther-
apy trials.
Two systematic reviews with meta- 
analyses evaluated treatment with INS for 
CRS with nasal polyps (40 RCTs; 3624 patients, 
mean age 48 years, 64% male) and without 
polyps (10 RCTs; 590 patients, mean age 
39 years, 51% male).1,2 Trials reported sino-
nasal symptom outcomes differently and 
couldn’t be combined. In addition to reduc-
ing rate of polyp occurrence, for both CRS 
with and without polyps, key findings were:
•   Global symptom scores were better for 
INS than placebo.  
•   Proportion of patients responding was 
greater for INS than with placebo.
There was no significant difference 
between adverse event rates with INS and 
placebo.  
A systematic review and meta-analysis 
(8 RCTs, 389 patients) compared different SI 
regimens for CRS.3 The standardized mean 
difference was used to combine trials using 
various symptom outcomes. Key findings 
included the following:    
•  SI was better than no treatment.   
•   SI adjunctive therapy (with an anti-
histamine) improved disease-specific 
quality-of-life scores. 
•   SI was less effective than INS therapy 
for symptom improvement.     
Hypertonic and isotonic saline yielded 
similar symptom scores. No adverse effects 
were reported.
One meta-analysis evaluated patient- 
reported outcomes with 12 weeks of mac-
rolide therapy compared to placebo using 
the results of the SinoNasal Outcome Test 
(SNOT). The SNOT is a quality-of-life ques-
tionnaire that lists symptoms and the social-
emotional consequences of CRS; a negative 
change in the SNOT score, on a 0 to 5 scale, 
indicates improvement. Overall the SNOT 
score improved 8% with macrolide therapy—
statistically significant, but of uncertain clini-
cal importance.4
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Surgery improves nasal obstruction,  
pain, and postnasal discharge
A systematic review of 21 studies (prospec-
tive RCTs, prospective controlled clinical 
trials, cohort studies, case series, and ret-
rospective record reviews) with a total of 
2070 patients analyzed the effectiveness 
of endoscopic sinus surgery alone for 
improving CRS symptoms.5 Mean duration 
of post-operative follow-up was 14 months. 
Meta-analysis was performed separately 
for each symptom and the standard mean 
difference of the symptom severity score 
before and after surgery was reported as the 
effect size (ES) for the outcome measure (an 
ES of 0.2 is considered small; 0.6, moderate; 
1.2, large; and 2, very large).                                                                                          
All symptoms improved compared to 
their preoperative severity scores. Nasal 
obstruction improved the most (ES=1.73; 95% 
CI, 1.45-2.02). Large symptom improvement 
was also observed for facial pain (ES=1.13; 
95% CI, 0.96-1.31) and postnasal discharge 
(ES=1.19; 95% CI, 0.96-1.43).
Surgery and medical therapy 
may provide comparable symptom relief
A recent Cochrane review of 4 low-quality 
RCTs including 378 patients compared surgical 
with medical interventions for CRS with nasal 
polyps. Study heterogeneity and selective out-
come reporting prevented meta-analysis.  
The 3 comparison groups were endo-
scopic sinus surgery vs systemic steroids + 
INS; polypectomy vs systemic steroid + INS; 
and endoscopic surgery + INS vs antibiotic 
+ “high-dose” INS. Overall, neither surgery 
nor medical therapy was superior in terms of 
patient-reported symptom scores or quality-
of-life measures.6                          JFP
TABLE
How medical treatment regimens for chronic rhinosinusitis compare
Treatment  
comparison
Outcome  
investigated
CRS patients  
with polyps?
Number 
of RCTs
Number of 
participants
Treatment 
duration
Results   
favor
Magnitude  
of effect
95% CI or 
P value
INS vs 
placebo1,2
Global   
symptom 
scores
Yes 7 445 2-24 wk INS SMD = -0.46 -0.65 to -0.27
No 5 286 1-6 mo INS SMD = -0.37 -0.60 to -0.13
Proportion  
responding to  
treatment
Yes 4 234 3 wk-1 yr INS 50% INS 
35% placebo
         —
No 4 263 2-20 wk INS 48% INS 
28% placebo
         —
Polyp  
recurrence
Yes 6 437 3 mo-1 yr INS RR = 0.59 0.45 to 0.79
SI vs no  
treatment3
Global     
symptom 
scores
No 3 129 1-6 mo SI SMD = 1.42 1.01 to 1.84
SI plus    
certrizine vs 
certrizine3
Rhinasthma 
disease-specific  
QoL scores
No 1 14 4 wk SI plus 
certrizine
92% upper 
airway score 
improvement
P=.02
INS vs isotonic  
or hypertonic  
SI3
Rhinoconjunctivitis  
disease-specific 
QoL scores
No 1 21 7 days INS Isotonic SI 
SMD = -3.29
-5.5 to -1.06
Hypertonic SI 
SMD = -2.88
-4.92 to -0.84
Hypertonic SI vs 
isotonic SI3
Disease-specific 
symptom scores
No 3 80 7 days Neither SMD = 0.34 -0.11 to 0.80
Macrolide vs 
placebo4
5-point SNOT  
QoL score
No 1 124 3 mo Macrolide SMD = -0.43 -0.82 to -0.05
CI, confidence interval; CRS, chronic rhinosinusitis; INS, intranasal steroid; QoL, quality of life; RCTs, randomized controlled trials; RR, relative risk; SI, saline irrigation; 
SMD, standard mean difference; SNOT, SinoNasal Outcome Test.
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